Skip to main content

Advertisement

Log in

Clinical pharmacokinetics of ciprofloxacin in patients with major burns

  • PHARMACOKINETICS AND DISPOSITION
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective: To better master the use of ciprofloxacin (CPF) in burn patients, a clinical study, including pharmacokinetics in serum and urine, was undertaken in a pathophysiologically homogeneous population of major-burn subjects.

Methods: Twelve major-burn patients who were infected with Pseudomonas aeruginosa, enterobacteria and gram-positive cocci, received CPF (600 mg t.i.d.). The mean body surface area affected by third-degree burns was 31.8 ± 14.5%. Two series of blood samples were drawn after the first and seventh doses; urine was collected during the first infusion. Levels of CPF in serum and urine were measured by means of high-performance liquid chromatography. A non-compartmental method was used for kinetic and graphic analysis of concentration–time pairs.

Results: No adverse effects were noted. Trough concentrations measured on day 3 (mean ± SD) were above the minimum inhibitory concentration (MIC) for the organism responsible for infection; i.e., 2.0 ± 1.2 μg · ml−1, and maximum concentrations were high 9.9 ± 3.4 μg · ml−1. An area under the concentration–time curve (AUC)/MIC ratio above 125 SIT−1 (where SIT is the serum inhibitory titer), which has been strongly correlated with clinical response and time to bacterial eradication, was achieved in 11 patients with a MIC of 0.5 μg · ml−1. There was a statistically significant difference between Cmin and AUC determined on day 1 and day 3. In contrast to healthy volunteers, CPF clearance rates were notably decreased.

Conclusion: The pharmacokinetics of CPF was altered in major-burn patients. The recommended dosage regimen for administration of CPF, i.e. 600 mg t.i.d. shows no adverse effects and a good microbiological efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 13 October 1998 / Accepted in revised form: 8 June 1999

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lesne-Hulin, A., Bourget, P., Ravat, F. et al. Clinical pharmacokinetics of ciprofloxacin in patients with major burns. E J Clin Pharmacol 55, 515–519 (1999). https://doi.org/10.1007/s002280050666

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002280050666

Navigation